Leonardi C, et al. - Researchers assessed the effectiveness and safety of ixekizumab through 156 weeks from the UNCOVER-3 study in patients who received the recommended dose regimen [160 mg at Week 0, 80 mg every 2 weeks (IXE Q2W) to Week 12, and 80 mg every 4 weeks (IXE Q4W) thereafter. They switched the patients randomized to IXE Q2W, IXE Q4W, etanercept twice weekly, or placebo IXE Q4W during long-term extension period. With the clearance of skin and nail lesions, ixekizumab sustained high responses, with no new safety concerns through 3 years. In patients with baseline scalp, nail, or palmoplantar involvement, similar response rates were observed.